CAR T-cell therapy for newly diagnosed primary plasma cell leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new treatment using your own immune cells, called CAR T-cells, to fight cancer cells in the blood. It is for people newly diagnosed with primary plasma cell leukemia, and aims to see if it is safe and effective as a first treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 75 years old.
- Have a new diagnosis of primary plasma cell leukemia, confirmed by tests.
- Have measurable signs of the disease, such as specific proteins in blood or urine.
- Be in good enough health (able to do daily activities with some help).
- Have a life expectancy of more than 3 months.
- Have suitable veins for a procedure to collect cells.
- Have had none or only up to 2 cycles of prior treatment for symptoms.
- Not have had certain types of previous therapy, like anti-BCMA treatment.
- Must be willing to use effective birth control during the study if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new Car T-cell treatment called CT0596 for patients with plasma cell leukemia, a rare and aggressive blood cancer. It aims to see if this therapy can help control the disease in patients who have already tried other treatments.
This trial tests a combination of drugs (bortezomib, lenalidomide, and dexamethasone) followed by a special cell therapy called CAR-T that targets a protein (BCMA) on cancer cells. It is for people with a rare and aggressive blood cancer called primary plasma cell leukemia who are not able to have a stem cell transplant.
This trial tests a treatment plan for newly diagnosed plasma cell leukemia that involves a stem cell transplant followed by two types of immunotherapy: CAR-T cells targeting BCMA and a bi-specific antibody targeting GPRC5D. The goal is to see if this approach can help keep the cancer in remission.
This trial tests a new immune cell therapy (CAR-T) that targets two markers on high-risk plasma cell cancers. It aims to see if this treatment is safe and helpful for people with aggressive or resistant forms of this disease.
This study is testing a new type of cell therapy (called CAR-T) that uses your own immune cells to attack the cancer cells in plasma cell tumors. It is designed for patients with multiple myeloma, plasma cell leukemia, plasmacytoma, or amyloidosis that has returned or not responded to standard treatments.
This trial tests a new type of cell therapy called CAR-T cells that are designed to recognize and attack cancer cells in patients with multiple myeloma, plasmacytoma, plasma cell leukemia, or light chain amyloidosis that have not responded well to previous treatments. The goal is to see if this approach can help patients whose cancers have become resistant to standard medicines.
Hear when a new Leukemia, Plasma Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.